107 related articles for article (PubMed ID: 22002175)
1. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder.
Schmahl C; Kleindienst N; Limberger M; Ludäscher P; Mauchnik J; Deibler P; Brünen S; Hiemke C; Lieb K; Herpertz S; Reicherzer M; Berger M; Bohus M
Int Clin Psychopharmacol; 2012 Jan; 27(1):61-8. PubMed ID: 22002175
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial.
Bohus MJ; Landwehrmeyer GB; Stiglmayr CE; Limberger MF; Böhme R; Schmahl CG
J Clin Psychiatry; 1999 Sep; 60(9):598-603. PubMed ID: 10520978
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.
Grant JE; Kim SW; Odlaug BL
Biol Psychiatry; 2009 Apr; 65(7):600-6. PubMed ID: 19217077
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients.
Guardia J; Roncero C; Galan J; Gonzalvo B; Burguete T; Casas M
Addict Behav; 2011 Mar; 36(3):265-9. PubMed ID: 21146937
[TBL] [Abstract][Full Text] [Related]
5. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
O'Malley SS; Sinha R; Grilo CM; Capone C; Farren CK; McKee SA; Rounsaville BJ; Wu R
Alcohol Clin Exp Res; 2007 Apr; 31(4):625-34. PubMed ID: 17374042
[TBL] [Abstract][Full Text] [Related]
6. The impact of personality disorders on alcohol-use outcomes in a pharmacotherapy trial for alcohol dependence and comorbid Axis I disorders.
Ralevski E; Ball S; Nich C; Limoncelli D; Petrakis I
Am J Addict; 2007; 16(6):443-9. PubMed ID: 18058408
[TBL] [Abstract][Full Text] [Related]
7. Borderline personality disorder and dissociation.
Ross CA
J Trauma Dissociation; 2007; 8(1):71-80. PubMed ID: 17409055
[TBL] [Abstract][Full Text] [Related]
8. [Naltrexone in the treatment of dissociative disorders--reflections with regard to a comprehensive therapeutic concept of borderline disorders].
Bolm T; Piegler T
Psychiatr Prax; 2001 Jul; 28(5):214-8. PubMed ID: 11479827
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pruritus with topically applied opiate receptor antagonist.
Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
[TBL] [Abstract][Full Text] [Related]
10. [Symptoms of DSM IV borderline personality disorder in a nonclinical population of adolescents: study of a series of 35 patients].
Chabrol H; Chouicha K; Montovany A; Callahan S
Encephale; 2001; 27(2):120-7. PubMed ID: 11407263
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone as a treatment for repetitive self-injurious behaviour:an open-label trial.
Roth AS; Ostroff RB; Hoffman RE
J Clin Psychiatry; 1996 Jun; 57(6):233-7. PubMed ID: 8666558
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of dissociative symptoms in borderline patients with naltrexone].
Schmahl C; Stiglmayr C; Böhme R; Bohus M
Nervenarzt; 1999 Mar; 70(3):262-4. PubMed ID: 10231814
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of dissociative symptoms in borderline personality disorder with naltrexone: supplementary comments].
Schmahl C; Bohus M
Nervenarzt; 2000 May; 71(5):427. PubMed ID: 10846724
[No Abstract] [Full Text] [Related]
14. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
15. An open trial of valproate in borderline personality disorder.
Stein DJ; Simeon D; Frenkel M; Islam MN; Hollander E
J Clin Psychiatry; 1995 Nov; 56(11):506-10. PubMed ID: 7592502
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
17. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
Malekzad F; Arbabi M; Mohtasham N; Toosi P; Jaberian M; Mohajer M; Mohammadi MR; Roodsari MR; Nasiri S
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):948-50. PubMed ID: 19453814
[TBL] [Abstract][Full Text] [Related]
19. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial.
Ziegenhorn AA; Roepke S; Schommer NC; Merkl A; Danker-Hopfe H; Perschel FH; Heuser I; Anghelescu IG; Lammers CH
J Clin Psychopharmacol; 2009 Apr; 29(2):170-3. PubMed ID: 19512980
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone effects on short-term and long-term smoking cessation.
Covey LS; Glassman AH; Stetner F
J Addict Dis; 1999; 18(1):31-40. PubMed ID: 10234561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
